• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Halozyme Therapeutics, Inc. - Common Stock (NQ:HALO)

85.76 +2.17 (+2.60%)
Streaming Delayed Price Updated: 4:00 PM EDT, Aug 6, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 2,704,018
Open 84.15
Bid (Size) 89.01 (100)
Ask (Size) 90.70 (600)
Prev. Close 83.59
Today's Range 82.60 - 86.00
52wk Range 61.23 - 86.00
Shares Outstanding 142,334,900
Dividend Yield N/A
Chart for  (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
News headline image
Halozyme Therapeutics Q2 Earnings Call Highlights ↗
Today 22:03 EDT
Halozyme Therapeutics (NASDAQ:HALO) reported record second-quarter revenue and raised its full-year outlook, citing growth in royalty income from its ENHANZE drug-delivery platform, contributions from... 
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics (NASDAQ:HALO) Beats Expectations in Strong Q2 CY2026, Guides for Strong Full-Year Sales
Today 16:45 EDT
Biopharmaceutical drug delivery company Halozyme Therapeutics (NASDAQ:HALO) reported Q2 CY2026 results beating Wall Street’s revenue expectations, with sales... 
Via StockStory

Performance

YTD
+22.0%
+22.0%
1 Month
+5.1%
+5.1%
3 Month
+31.6%
+31.6%
6 Month
+9.4%
+9.4%
1 Year
+37.6%
+37.6%

More News

Read More
News headline image
What To Expect From Halozyme Therapeutics’s (HALO) Q2 Earnings
August 04, 2026
Via StockStory
News headline image
3 Growth Stocks Set to Flourish
August 03, 2026
Via StockStory
Halozyme Therapeutics (NASDAQ:HALO): A Value Stock Profile Offering Strong Profitability and a Low Forward P/E ↗
June 25, 2026
Via Chartmill
Halozyme Therapeutics Inc (NASDAQ:HALO): A Deep Value Play Combining Strong Profitability with an Attractive 14.35 P/E ↗
June 03, 2026
Via Chartmill
Halozyme Therapeutics (NASDAQ:HALO) Surges After Q1 Beat, Launches $1 Billion Buyback ↗
May 11, 2026
Via Chartmill
News headline image
1 Cash-Producing Stock on Our Watchlist and 2 We Ignore
July 24, 2026
Via StockStory
Topics Energy
News headline image
1 Value Stock Worth Investigating and 2 Facing Headwinds
July 15, 2026
Via StockStory
News headline image
2 Reasons to Like HALO and 1 to Stay Skeptical
July 10, 2026
Via StockStory
Topics Stocks
News headline image
1 Surging Stock for Long-Term Investors and 2 We Brush Off
July 01, 2026
Via StockStory
News headline image
2 Profitable Stocks Worth Your Attention and 1 We Question
June 18, 2026
Via StockStory
Topics Credit Cards
News headline image
Why Is Halozyme Therapeutics (HALO) Stock Rocketing Higher Today
June 03, 2026
Via StockStory
Topics Economy
News headline image
Halozyme Therapeutics’s Q1 Earnings Call: Our Top 5 Analyst Questions
May 18, 2026
Via StockStory
Topics Earnings
News headline image
Thermo Fisher, Dentsply Sirona, Collegium Pharmaceutical, and Halozyme Therapeutics Stocks Trade Down, What You Need To Know
May 13, 2026
Via StockStory
Topics Economy
News headline image
Therapeutics Stocks Q1 Recap: Benchmarking Halozyme Therapeutics (NASDAQ:HALO)
May 12, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
HALO Q1 Deep Dive: Royalty Expansion and Pipeline Progress Shape 2026 Outlook
May 12, 2026
Via StockStory
News headline image
Halozyme (HALO) Q1 2026 Earnings Transcript ↗
May 11, 2026
Via The Motley Fool
News headline image
Halozyme Therapeutics Q1 Earnings Call Highlights ↗
May 11, 2026
Via MarketBeat
Topics Earnings
News headline image
Halozyme Therapeutics’s (NASDAQ:HALO) Q1 CY2026 Sales Top Estimates
May 11, 2026
Via StockStory
News headline image
Halozyme Therapeutics Earnings: What To Look For From HALO
May 09, 2026
Via StockStory
Topics Artificial Intelligence
News headline image
1 of Wall Street’s Favorite Stock with Exciting Potential and 2 That Underwhelm
April 21, 2026
Via StockStory
News headline image
3 Cash-Producing Stocks with Exciting Potential
April 10, 2026
Via StockStory
News headline image
2 Small-Cap Stocks with Solid Fundamentals and 1 We Ignore
April 09, 2026
Via StockStory
News headline image
1 Small-Cap Stock for Long-Term Investors and 2 We Brush Off
April 08, 2026
Via StockStory

Frequently Asked Questions

Is Halozyme Therapeutics, Inc. - Common Stock publicly traded?
Yes, Halozyme Therapeutics, Inc. - Common Stock is publicly traded.
What exchange does Halozyme Therapeutics, Inc. - Common Stock trade on?
Halozyme Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Halozyme Therapeutics, Inc. - Common Stock?
The ticker symbol for Halozyme Therapeutics, Inc. - Common Stock is HALO on the Nasdaq Stock Market
What is the current price of Halozyme Therapeutics, Inc. - Common Stock?
The current price of Halozyme Therapeutics, Inc. - Common Stock is 85.76
When was Halozyme Therapeutics, Inc. - Common Stock last traded?
The last trade of Halozyme Therapeutics, Inc. - Common Stock was at 08/06/26 04:00 PM ET
What is the market capitalization of Halozyme Therapeutics, Inc. - Common Stock?
The market capitalization of Halozyme Therapeutics, Inc. - Common Stock is 12.21B
How many shares of Halozyme Therapeutics, Inc. - Common Stock are outstanding?
Halozyme Therapeutics, Inc. - Common Stock has 12B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap